Home About Us Industry Report Store Resources Contact us

Radioactive Tracer Market Research Report 2024

Radioactive Tracer Market Global Industry Analysis and Forecast (2023-2030) By Type (Diagnostic Radioactive Tracers, Therapeutic Radioactive Tracers), Test Type (PET, SPECT), Application (Oncology, Pulmonary, Neurology, Cardiology) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes) And Region

0/5
( 0 votes )

Report ID: 358

Categories: Healthcare

Format :

Summary TOC Segmentation Methodology

Radioactive Tracer Market Synopsis

The Radioactive Tracer Market Size Was Valued at USD 3.24 Billion in 2023 and is Projected to Reach USD 6.07 Billion by 2032, Growing at a CAGR of 7.22 % From 2024-2032.

Radioactive tracers are substances that contain radioactive isotopes, used to trace the movement of materials within a system. They emit radiation that can be detected and measured, aiding in understanding processes such as fluid flow, chemical reactions, and biological pathways in research, industry, and medical diagnostics.

  • The radioactive tracers market involves the use of radioactive materials to track and analyze biological processes, medical conditions, industrial operations, and environmental behaviors. These tracers emit radiation that can be detected and measured, providing valuable insights into various applications. In medicine, they are crucial for diagnostic imaging, such as PET scans, to visualize and assess organ function and disease progression. In industry, radioactive tracers are used for process optimization, monitoring fluid flow in pipelines, and studying material behavior under specific conditions. Environmental applications include tracking pollutants and understanding ecosystem dynamics.
  • The market for radioactive tracers is driven by increasing demand for advanced diagnostic techniques in healthcare, growing applications in industrial processes to enhance efficiency and safety, and rising environmental concerns requiring precise monitoring solutions. Technological advancements in radiopharmaceuticals and imaging techniques continue to expand their utility and accuracy, further boosting market growth. Regulatory approvals and safety standards play a critical role in market expansion, ensuring safe handling and disposal of radioactive materials. As the need for precise and non-invasive diagnostic tools grows globally, the radioactive tracers market is poised for continued expansion across medical, industrial, and environmental sectors.

Top Key Players Involved Are:

"GE Healthcare (USA), Cardinal Health (USA), Lantheus Medical Imaging (USA), Curium Pharma (France), Nordion (Canada), Bracco Imaging (Italy), Eckert & Ziegler (Germany), Jubilant DraxImage (Canada), NTP Radioisotopes (South Africa), IBA Molecular (Belgium), Australian Nuclear Science and Technology Organization (ANSTO) (Australia), China Isotope & Radiation Corporation (CIRC) (China), Institute for Radioelements (IRE) (Belgium), IRE ELiT (Belgium), PetNet Solutions (USA), Isologic Innovative Radiopharmaceuticals (Canada), Institute of Isotopes Co., Ltd. (Hungary), Alliance Medical (UK), RadioMedix Inc. (USA), BV Cyclotron VU (Netherlands), Other Active Players."

Radioactive Tracer Market Trend Analysis

Increasing Incidence of Chronic Diseases

  • The increasing incidence of chronic diseases has significantly propelled the demand for radioactive tracers in the medical field. These tracers play a crucial role in diagnostic imaging procedures such as PET scans, SPECT scans, and other nuclear medicine techniques. Chronic diseases like cancer, cardiovascular diseases, and neurological disorders often require precise imaging for accurate diagnosis, staging, and treatment monitoring. Radioactive tracers, which emit gamma rays or positrons, allow healthcare providers to visualize physiological functions, metabolic pathways, and disease progression at a molecular level.
  • Moreover, advancements in medical technology have led to the development of new radiopharmaceuticals with improved targeting capabilities and reduced side effects, further driving market growth. The growing elderly population globally, who are more susceptible to chronic conditions, also contributes to the increasing demand for diagnostic imaging using radioactive tracers.
  • Additionally, government initiatives promoting healthcare infrastructure development and the rising awareness among patients about early disease detection and personalized medicine are key factors boosting the radioactive tracer’s market.

 Growing Applications in Medical Diagnostics

  • The Radioactive Tracers market is poised for significant growth, driven by expanding applications in medical diagnostics. These tracers play a crucial role in various diagnostic techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). PET and SPECT scans using radioactive tracers enable detailed imaging of tissues and organs, aiding in the diagnosis of diseases like cancer, cardiovascular conditions, and neurological disorders.
  • Advancements in radiopharmaceuticals, which incorporate radioactive tracers, are enhancing their specificity and efficacy in detecting physiological changes at a molecular level. This capability not only improves diagnostic accuracy but also supports personalized medicine approaches by tailoring treatments based on individual patient responses. Moreover, the rising prevalence of chronic diseases globally is fueling the demand for accurate diagnostic tools, further driving market growth.
  • Regulatory approvals for new radiopharmaceuticals and ongoing research and development efforts to expand tracer applications are expected to sustain market momentum.

Radioactive Tracer Market Segment Analysis:

The Radioactive Tracer Market is Segmented based on Type, Test Type, Application, End User, and Region

By Type, the Therapeutic Radioactive Tracers segment is expected to dominate the market during the forecast period

  • In the Radioactive Tracers market, the Therapeutic Radioactive Tracers segment is poised to dominate due to increasing applications in oncology and neurology. These tracers are crucial in diagnosing and treating various cancers and neurological disorders by pinpointing abnormal cells or areas in the body. The growth of this segment is driven by advancements in radiopharmaceuticals, which enhance the efficacy and specificity of treatments, thereby reducing side effects and improving patient outcomes.
  • Therapeutic radioactive tracers, such as iodine-131 for thyroid cancer and lutetium-177 for neuroendocrine tumors, are increasingly adopted in clinical settings worldwide. Their ability to deliver targeted radiation directly to diseased tissues or cells while sparing healthy tissues makes them indispensable in modern medicine. Moreover, ongoing research and development activities aimed at expanding the range of therapeutic applications further bolster market growth.

By Application, the Oncology segment held the largest share in 2023

  • In 2023, the Oncology segment dominated the Radioactive Tracers market, holding the largest share due to its critical role in diagnostic imaging and therapy for cancer treatment. Radioactive tracers are extensively used in oncology for imaging tumors, monitoring treatment efficacy, and planning radiation therapy. The growing incidence of cancer globally, coupled with advancements in nuclear medicine techniques, has significantly bolstered the demand for radioactive tracers in oncology applications.
  • Key factors driving the Oncology segment include the increasing adoption of PET (Positron Emission Tomography) scans, which rely heavily on radioactive tracers for precise imaging of tumors and metastases. Additionally, the development of novel tracers with better imaging characteristics and therapeutic efficacy has expanded the application scope within oncology. Pharmaceutical companies and research institutions are investing in R&D to innovate new tracers that can target specific cancer types and improve diagnostic accuracy.

Radioactive Tracer Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast Period

  • The North American region is poised to dominate the radioactive tracer’s market, driven by advanced healthcare infrastructure, significant research and development activities, and robust technological advancements. The United States, in particular, holds a prominent position due to its strong presence of pharmaceutical and biotechnology companies, research institutions, and academic centers dedicated to medical imaging and diagnostics.
  • Key factors contributing to North America's leadership in this market include substantial investments in healthcare, favorable government initiatives supporting research in nuclear medicine, and a well-established regulatory framework ensuring safe usage of radioactive tracers. Moreover, the increasing prevalence of chronic diseases like cancer and cardiovascular disorders fuels the demand for advanced diagnostic tools, where radioactive tracers play a crucial role in accurate disease detection and treatment monitoring.
  • Furthermore, strategic collaborations between academic research institutions and industry players further enhance the region's capabilities in developing innovative tracer technologies. As the healthcare sector continues to evolve with a focus on precision medicine and personalized healthcare solutions, North America is expected to maintain its dominant position in the global radioactive tracers market, contributing significantly to advancements in medical diagnostics and therapeutic applications.

Active Key Players in the Radioactive Tracer Market

  • GE Healthcare (USA)
  • Cardinal Health (USA)
  • Lantheus Medical Imaging (USA)
  • Curium Pharma (France)
  • Nordion (Canada)
  • Bracco Imaging (Italy)
  • Eckert & Ziegler (Germany)
  • Jubilant DraxImage (Canada)
  • NTP Radioisotopes (South Africa)
  • IBA Molecular (Belgium)
  • Australian Nuclear Science and Technology Organization (ANSTO) (Australia)
  • China Isotope & Radiation Corporation (CIRC) (China)
  • Institute for Radioelements (IRE) (Belgium)
  • IRE ELiT (Belgium)
  • PetNet Solutions (USA)
  • Isologic Innovative Radiopharmaceuticals (Canada)
  • Institute of Isotopes Co., Ltd. (Hungary)
  • Alliance Medical (UK)
  • RadioMedix Inc. (USA)
  • BV Cyclotron VU (Netherlands), Other Active Players

Key Industry Developments in the Radioactive Tracer Market:

  • In March 2023, Telix Pharmaceuticals received FDA approval for a supplementary New Drug Application (sNDA) for Illuccix, a kit designed to prepare gallium Ga 68 gozetotide injection. The approval allows Illuccix to select patients with metastatic prostate cancer who could benefit from 177Lu 177 PSMA-directed therapy.
  • In Sep 2023, Curium, a leader in nuclear medicine, announced that it had entered into an exclusive rights agreement with b.e. Imaging, an imaging center, for the distribution of PYLCLARI (INN: Piflufolastat (18F) formerly known as (18F)-DCFPyL), indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography in adults with prostate cancer. Under the terms of the agreement, b.e. Imaging will be responsible for obtaining marketing authorization from Swiss competent authority Swissmedic and will have exclusive distribution rights for PYLCLARI across Switzerland.

Global Radioactive Tracer Market

Base Year:

2023

Forecast Period:

2024-2032

Historical Data:

2017 to 2023

Market Size in 2023:

USD 3.24 Bn.

Forecast Period 2024-32 CAGR:

7.22 %

Market Size in 2032:

USD 6.07 Bn.

Segments Covered:

By Type

  • Diagnostic Radioactive Tracers
  • Therapeutic Radioactive Tracers

By Test Type

  • PET
  • SPECT

By Application

  • Oncology
  • Pulmonary
  • Neurology
  • Cardiology

By End User

  • Hospitals & Clinics
  • Diagnostic Centers
  • Academic & Research Institutes

By Region

  • North America (U.S., Canada, Mexico)
  • Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
  • Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
  • Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC)
  • Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
  • South America (Brazil, Argentina, Rest of SA)

Frequently Asked Questions

What would be the forecast period in the Radioactive Tracer Market research report?

The forecast period in the Radioactive Tracer Market research report is 2024-2032.

Who are the key players in the Radioactive Tracer Market?

GE Healthcare (USA), Cardinal Health (USA), Lantheus Medical Imaging (USA), Curium Pharma (France), Nordion (Canada), Bracco Imaging (Italy), Eckert & Ziegler (Germany), Jubilant DraxImage (Canada), NTP Radioisotopes (South Africa), IBA Molecular (Belgium), Australian Nuclear Science and Technology Organization (ANSTO) (Australia), China Isotope & Radiation Corporation (CIRC) (China), Institute for Radioelements (IRE) (Belgium), IRE ELiT (Belgium), PetNet Solutions (USA), Isologic Innovative Radiopharmaceuticals (Canada), Institute of Isotopes Co., Ltd. (Hungary), Alliance Medical (UK), RadioMedix Inc. (USA), BV Cyclotron VU (Netherlands), Other Active Players.

What are the segments of the Radioactive Tracer Market?

The Radioactive Tracer Market is segmented into Type, Test Type, Application, End User, and Region. Type the market is categorized into (Diagnostic Radioactive Tracers, Therapeutic Radioactive Tracers), Test Type the market is categorized into (PET, SPECT), Application the market is categorized into (Oncology, Pulmonary, Neurology, Cardiology) End User the market is categorized into (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes). By region, it is analyzed across North America (U.S.; Canada; Mexico), Eastern Europe (Bulgaria; The Czech Republic; Hungary; Poland; Romania; Rest of Eastern Europe), Western Europe (Germany; UK; France; Netherlands; Italy; Russia; Spain; Rest of Western Europe), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).

What is the Radioactive Tracer Market?

Radioactive tracers are substances that contain radioactive isotopes, used to trace the movement of materials within a system. They emit radiation that can be detected and measured, aiding in understanding processes such as fluid flow, chemical reactions, and biological pathways in research, industry, and medical diagnostics.

How big is the Radioactive Tracer Market?

Radioactive Tracer Market Size Was Valued at USD 3.24 Billion in 2023, and is Projected to Reach USD 6.07 Billion by 2032, Growing at a CAGR of 7.22 % From 2024-2032.

Select Licence Type

Single User

US$ 3200

Corporate User

US$ 4500

Excel Datapack

US$ 1500

Yearly Membership/Subscription

Connect with our sales team

Why Pristine Intelligence LLP

100%

Customer
Satisfaction

24x7+

Availability - we are always
there when you need us

200+

Fortune 50 Companies trust
Pristine Intelligence LLP

80%

of our reports are exclusive
and first in the industry

100%

more data
and analysis

1000+

reports published
till date